Buckley mayor fined nearly $15k over missing campaign forms
This story was originally published on MyNorthwest.com.
Buckley Mayor Beau Burkett has racked up a bill of nearly $15,000 worth in fines.
The fines are mostly related to breaking campaign finance laws, including having late or missing financial disclosures, according to The Tacoma News Tribune. The latest fine was a $1,000 charge filed last week for not reporting personal debt on a 2023 form, with his total amount owed reaching $14,850 in fines.
The Public Disclosure Commission (PDC) states that all elected officials must file financial statements to ensure transparency. Candidates running for public office in Washington must file an F-1 Personal Financial Affairs Statement, which documents the candidate's salary range, the real estate they own, and membership on boards of committees, among other important information.
According to The Tacoma News Tribune, Burkett did not turn in F-1 forms for 2015, 2016, 2017, 2018, and 2019. In 2021, while running in the mayoral race, he didn't turn in his 2020 F-1 or his C-1 candidate registration form. When requested to file the paperwork accordingly, he failed to include and disclose the $13,850 he owed in fines to the PDC.
'Mayor Burkett is one of the approximately 5-10% of people who don't correct their forms when contacted by PDC staff,' Edwards wrote in an email to The News Tribune. 'Despite this, and despite the many thousands of dollars that Mayor Burkett already owes the agency for years of ignoring the law, the PDC still offered to suspend virtually all of today's penalty if he corrects his F1 report.'
Burkett did not appear at last week's hearing. KIRO Newsradio has reached out for comment. Burkett's term as mayor ends December 31, and the fines have been sent to collections.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
42 minutes ago
- Bloomberg
Stock Movers: JM Smucker, McDonald's, Steel Stocks
On this edition of Stock Movers: - JM Smucker (SJM) shares declined the most in nearly four decades after saying US tariffs increasing costs in its coffee business will hurt profit, continuing a challenging run for the biggest US packaged food producers. The company, which owns the Folgers and Cafe Bustelo coffee brands, said adjusted earnings this fiscal year will be as much as $9.50 a share. The impact of higher coffee costs and US levies reduced that forecast by roughly $1 a share, Smucker said. - McDonald's (MCD) shares slipped on Tuesday after Redburn Atlantic gave the burger chain its sole sell rating, saying shifting consumer patterns due to weight-loss drugs and inflation are cause for concern. Shares of McDonald's fell as much as 1.8% to a March low on the downgrade, a two-notch cut from Redburn's previous buy rating. Redburn held a buy rating on the stock since initiating coverage in 2023. As more Americans turn to GLP-1 drugs like Ozempic to lose weight, McDonald's could see as much as a $428 million annual impact to revenue, representing about 1% of system sales, Redburn Atlantic analysts Chris Luyckx and Edward Lewis wrote. 'A 1% drag today could easily build to 10% or more over time, particularly for brands skewed toward lower-income consumers or group occasions.' - Steel shares such as Nucor (NUE) and Cleveland-Cliffs (CLF) dropped after Bloomberg News reported that US and Mexico are closing in on a deal that would remove President Donald Trump's 50% tariffs on steel imports up to a certain volume, according to people familiar with the matter, a revamp of a similar deal between the trade partners during his first term. Trump hasn't been directly involved in the negotiations and would need to sign off on any deal. The talks are being led by Commerce Secretary Howard Lutnick, according to the people, who asked not to be identified as the discussions are private. The people said the agreement hasn't been finalized. Under its current terms, it would allow US buyers to import Mexican steel duty-free as long as they kept total shipments below a level based on historical trade volumes, according to the people. The new cap would be higher than what was allowed under a similar deal during Trump's first term, they said, which was never a fixed figure but designed to 'prevent surges.'
Yahoo
an hour ago
- Yahoo
Redburn Turns Bearish on McDonald's (MCD), Domino's (DPZ) Amid GLP-1 Impact Concerns
Redburn Atlantic downgraded McDonald's (MCD, Financials) and launched coverage of Domino's Pizza (DPZ, Financials) with a Sell rating Tuesday, warning that appetite-suppressing weight-loss drugs like GLP-1s could reshape consumer dining habits long term. In a note, the firm said that while structural growth has benefited the sector for years, emerging behavioral shifts and economic fatigue may threaten that momentum. Even a 1% decline in demand today, Redburn warned, could snowball into double-digit erosion over time as GLP-1 use expands. These drugs which reduce appetite and support weight loss may lower not only individual consumption, but also disrupt group dining routines and habitual fast-food behavior, Redburn analysts wrote. McDonald's was downgraded from Buy to Sell on concerns about traffic weakness, rising menu fatigue, and vulnerability to pricing shocks. Redburn also flagged that U.S. consumers may face added pressure from renewed inflation and tariffs, reducing room for further price hikes. The firm gave Domino's a Sell rating on similar concerns, but upgraded Yum! Brands (YUM, Financials) to Buy, citing its international footprint and conservative valuation. Coverage of Chipotle (CMG, Financials) was initiated at Neutral. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
an hour ago
- CBS News
McDonald's shares slip after downgrade spurred by weight-loss drug popularity
McDonald's shares dropped Tuesday as weight-loss drugs threaten to take a big bite out of the fast food chain's earnings. Shares were down by as much as 1.7% Tuesday, after equity analysis firm Redburn Atlantic downgraded the burger giant's stock rating two notches, from buy to sell. Changes in Americans' eating habits spurred by the use of the class of drugs known as GLP-1s, which are designed to help regulate users' blood sugar and appetite, pose an underappreciated threat to some food businesses, according to Redburn Atlantic analysts Chris Luyckx and Edward Lewis. As a result, McDonald's could lose up to 28 million customer visits, resulting in a revenue loss of $482 million per year — about 0.9% of the company's sales, according to the analysis. The appetite-suppressing drugs are expected to have a transformative effect on how Americans consume food. At particular risk are brands that cater to lower-income consumers — a category to which McDonald's belongs. That's because spending on food away from home among lower-income households who start using GLP-1 drugs declines and tends to remain depressed, according to the report, creating "material implications for chains with broad mass-market exposure." Higher-income users of the drugs, by contrast, decrease their spending before reverting to old spending patterns within one year, the analysis found. "Behaviour changes extend beyond the individual user — reshaping group dining, influencing household routines and softening habitual demand. A 1% drag today could easily build to 10% or more over time, particularly for brands skewed toward lower income consumers or group occasions," the analysts said in a research note. Pricing fatigue Inflationary pressures and consumers' strained budgets only compound problems for McDonald's, according to the report. "Consumers are showing clear signs of pricing fatigue after years of aggressive menu inflation," the analysts wrote. "Although the gap between eating out and at home has narrowed, it remains historically wide, reinforcing value concerns." The Redburn analysis refers to GLP-1 drugs like Ozempic and Wegovy as "demand disruptors" for restaurants like McDonald's, because they reduce users' appetites and limit the number of calories they consume each day. These features of the drugs "could have serious implications for the restaurant industry," Redburn analysts wrote. To be sure, adoption of the drugs is not yet widespread, with just 12% of U.S. adults ever having tried the meds. Currently, only 6% of the adult population uses the drugs. Wider adoption of GLP-1 drugs for weight loss could ultimately lead to a broad-based reduction in Americans' caloric intake at restaurants, including fast food joints, reversing a decades-long trend. From 1977 to 2018, the total share of calories consumed at restaurants nearly tripled, according to Redburn Atlantic's analysis of U.S. Department of Agriculture data. Compared with other fast food brands, McDonald's is the most exposed to taking a hit from the increased usage of GLP-1 drugs, according to the research. More pressing challenges However, Peter Saleh, managing director and restaurant and food distributors analyst at BTIG global financial services, said McDonald's is facing other headwinds, and he wouldn't expect GLP-1s to meaningfully eat into its earnings, at least not in the near-term. For one, McDonald's core customer base consists of low- and middle-income consumers who are unlikely to be able to afford GLP-1 drugs, said Saleh, who doesn't foresee there being much overlap between the fast food giant's patrons and adopters of the drugs. "I don't think there would be a meaningful GLP-1 impact on McDonald's right now, but that's not to say that in three or four years that won't be the case," he said. "I just don't think we are there yet."
